Related Experiment Video

Updated: Feb 28, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

GLP-1 Receptor Agonist Prescription Patterns in the All of Us Research Program

Angela Gasdaska¹, Benjamin Tyndall¹, Ed Preble¹

¹RTI International, Research Triangle Park, NC.

Medrxiv : the Preprint Server for Health Sciences

|February 26, 2026

Abstract

Importance:

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are fast-growing treatments for type 2 diabetes, obesity, and sleep apnea and are under investigation as potential treatments for many other conditions. The National Institutes of Health's (NIH's) All of Us Research Program offers a robust observational data source for studying questions related to GLP-1RA use in real-world settings.

Objective:

This article describes key characteristics of All of Us participants who have been prescribed GLP-1RAs. The goals are to present the utility of the All of Us data and describe the strengths and limitations of using this resource for future research on GLP-1RAs.

Design:

Using the All of Us Controlled Tier Curated Data Repository version 8 (CDRv8), we provide a descriptive analysis of the cohort with GLP-1RA records using cross-sectional surveys, longitudinal electronic health record (EHR) data, and longitudinal Fitbit data.

Setting:

The All of Us Research Program is a large, federally funded, longitudinal cohort study established in 2018 by NIH. Recruitment efforts are nationwide and target a range of populations to advance precision medicine for all.

Participants:

Participants are U.S. residents, aged 18 or older at the time of study consent, who were enrolled between May 6, 2018, and October 1, 2023.

Exposures:

The GLP-1RA cohort included participants with at least two GLP-1RA prescription records on different days at any time point based on their EHRs.

Main Outcomes:

Frequencies and medians for a range of sociodemographic characteristics, health care utilization patterns, comorbid conditions, GLP-1RA prescription trends, laboratory and observation availability, and Fitbit data.

Results:

The All of Us GLP-1RA cohort is large (n=15 477), with high data availability across a range of relevant data types. These participants are older and have more comorbid conditions than the entire CDRv8 population. Prescription trends indicate rapid uptake of GLP-1RA drugs since 2014.

Conclusions And Relevance:

All of Us CDRv8 is a valuable resource for research on GLP-1RAs across a large, heterogeneous cohort of participants. The variety and availability of data offer many possibilities for future observational, real-world research to address unanswered questions about GLP-1RA use and replicate recent findings generated from other datasets.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Articles linked to this work by shared authors, journal, and citation graph.

Holistic Health Approaches for People With Alcohol Use Disorder: Protocol for a Scoping Review.

JMIR research protocols·2026

Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort.

Alcohol, clinical & experimental research·2026

A Secondary, Subgroup Analysis of Alcohol Cue-Exposure Craving in Response to Pharmacological Inhibition of the Growth Hormone Secretagogue Receptor With PF-5190457.

Alcohol, clinical & experimental research·2026

Predicting Outpatient Follow-Up Retention After Inpatient Treatment in Patients With Alcohol Use Disorder: A Data-Driven Random Forest Approach.

Addiction biology·2026

The All of Us Research Program's wearables dataset.

Nature medicine·2026

Acute metabolic effects of cannabinoid receptor modulators during sequential hyperglycemic, euglycemic-hyperinsulinemic clamps in healthy individuals.

American journal of physiology. Endocrinology and metabolism·2026

See all related articles